fbpx
EVENTS|NEWS|CONTACT|DONATE
Read Our Newsletter

News in Gastric Cancer

News from around the world, curated by the Gastric Cancer Foundation.
nivolumab opdivo
Mar 18 2021

Quality of Life Maintained With Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

A study presented at ASCO GI found that the immunotherapy drug Opdivo given to gastric cancer patients after surgery lowers relapse risk without lessening their quality of life.

Read Source
,

Social Media

   

Newsroom

For press inquiries about the Gastric Cancer Foundation, please contact: Mediainfo@gastriccancer.org

Please join with us to fuel the next wave of progress.

Your support today will honor the memories of those we have lost and create much-needed hope for those who are bravely facing the disease today. Contributions are tax-deductible.
Please join with us to fuel the next wave of progress. Support our 2024 Fundraising Campaign.

Your support today will honor the memories of those we have lost and create much-needed hope for those who are bravely facing the disease today. Contributions are tax-deductible.

Together, we will defeat stomach cancer.

Together, we will defeat stomach cancer.

MORE INFODONATE
X